Engineering ApoE‐Mimetic HDL‐Like Nanoparticles for Glioblastoma‐Targeted Theranostics
Small Methods · 04.11.2026
DOI: 10.1002/smtd.71168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small Methods, online erschienen am 04.11.2026. Verfasst von Hanyi Weng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Terry Fox Research Institute, Canadian Institute for Health Research, Canada Foundation for Innovation.
Abstract (Originalsprache)
Glioblastoma theranostics remain limited by the tumor's blood–brain‐barrier (BBB), infiltrative growth, and heterogenous, treatment‐resistant cell populations. Here, we engineered self‐assembled high‐density lipoprotein (HDL)‐like nanoparticles functionalized with an apolipoprotein E–mimetic peptide (ApoEm), designed to recapitulate and strengthen the multireceptor‐mediated transport properties of native apolipoprotein E3 (ApoE3). Competition and receptor inhibition studies demonstrate coordinated uptake of ApoEm‐HDL nanoparticle via low‐density lipoprotein receptor, low‐density lipoprotein receptor–related protein 1, and scavenger receptor class‐B type 1, which are expressed at BBB and upregulated in glioblastoma. Incorporation of porphyrin‐lipid into the HDL‐like scaffold yielded ApoEm porphyrin–lipoprotein nanoparticles (ApoEm‐PLP) with a uniform, spherical morphology (∼30 nm). ApoEm‐PLP increased porphyrin uptake relative to ApoE3‐PLP across multiple glioblastoma cell lines (∼seven‐fold in U87 cells, ∼four‐fold in T98, and GL261‐Luc cells) and induced ∼two‐fold greater photodynamic therapy (PDT) efficacy in U87 cells. In an orthotopic U87 glioblastoma model, intravenous administration of ApoEm‐PLP achieved ∼13‐fold higher tumor porphyrin accumulation than normal brain, with homogeneous intratumoral distribution and pronounced peri‐tumoral deposition. Transcranial PDT using ApoEm‐PLP elicited widespread tumor damage. These findings establish ApoEm‐HDL‐like nanoparticles as a promising theranostic platform for uniform glioblastoma porphyrin delivery and effective phototherapy, with potential to address the infiltrative and heterogenous nature of glioblastoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
- Department of Medical Biophysics, University of Toronto, Toronto, Canada.
- Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
- Department of Medicine at the Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
ORCID-Profile: Yiming Yang, Yulin Mo, Madeline K Brown, Juan Chen, Gang Zheng
Förderung
- Terry Fox Research Institute
- Canadian Institute for Health Research
- Canada Foundation for Innovation
- Canada Research Chairs Program
- Princess Margaret Cancer Foundation
Zitieren
APA
Weng, H., Cui, R. W., Gong, L. X., Qian, A., Ding, L., Kwon, N., Yang, Y., Mo, Y., Ho, T., Brown, M. K., Rajora, M. A., Chen, J., & Zheng, G. (2026). Engineering ApoE‐Mimetic HDL‐Like Nanoparticles for Glioblastoma‐Targeted Theranostics. Small Methods. https://doi.org/10.1002/smtd.71168
Vancouver
Weng H, Cui RW, Gong LX, Qian A, Ding L, Kwon N, et al. Engineering ApoE‐Mimetic HDL‐Like Nanoparticles for Glioblastoma‐Targeted Theranostics. Small Methods. 2026. doi:10.1002/smtd.71168
BibTeX
@article{Weng2026,
author = {Weng, Hanyi and Cui, Rick Wentao and Gong, Ling Xi and Qian, Ashley and Ding, Lili and Kwon, Nahyun and Yang, Yiming and Mo, Yulin and Ho, Tiffany and Brown, Madeline K and Rajora, Maneesha Amrita and Chen, Juan and Zheng, Gang},
title = {Engineering ApoE‐Mimetic HDL‐Like Nanoparticles for Glioblastoma‐Targeted Theranostics},
journal = {Small Methods},
year = {2026},
doi = {10.1002/smtd.71168}
}
EUVIMED